Cervical cancer is a major cause of morbidity and mortality particularly in low- and mid-income countries. This review synthesizes existing knowledge on cervical cancer, HPV infection, and HPV vaccination accumulated over the past decade (2015-2024), highlighting disparities in awareness and prevention strategies globally. Education level correlates with HPV vaccine awareness, yet mere familiarity with cervical cancer doesn't ensure understanding of its severity. Notably, prevention measures, including screening and HPV testing, varied significantly across countries during this period. To enhance HPV vaccine uptake moving forward, targeted efforts are necessary to educate women, particularly in low- and mid-income countries, about HPV risks as a sexually transmitted disease and the availability of affordable vaccines in government clinics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.currproblcancer.2024.101157 | DOI Listing |
Int J Clin Oncol
January 2025
Translational Research Support Section, National Cancer Center Hospital East, Chiba, Japan.
Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.
View Article and Find Full Text PDFJ Transl Med
January 2025
Department of Radiation Oncology, The Second Affiliated Hospital of Dalian Medical University, No. 467 of Zhongshan Road, Shahekou District, Dalian, 116023, China.
Objective: Cervical cancer is a common malignancy among women, and radiotherapy remains a primary treatment modality across all disease stages. However, resistance to radiotherapy frequently results in treatment failure, highlighting the need to identify novel therapeutic targets to improve clinical outcomes.
Methods: The expression of molecule interacting with CasL-2 (MICAL2) was confirmed in cervical cancer tissues and cell lines through western blotting (WB) and immunohistochemistry (IHC).
BMC Cancer
January 2025
Department of Community & Family Medicine, All India Institute of Medical Sciences, 151001, Bathinda, Punjab, India.
Introduction: Existing evidence suggests a lower uptake of cervical cancer screening among Indian women. Coverage is lower in rural than urban women, but such disparities are less explored. So, the present study was conducted to explore the self-reported coverage of cervical cancer screening in urban and rural areas stratified by socio-demographic characteristics, determine the spatial patterns and identify any regional variations, ascertain the factors contributing to urban-rural disparities and those influencing the likelihood of screening among women aged 30-49 years factors residing in urban, rural, and overall Indian settings.
View Article and Find Full Text PDFNPJ Precis Oncol
January 2025
Tissue Image Analytics Centre, Department of Computer Science, University of Warwick, Coventry, United Kingdom.
Sci Rep
January 2025
Department of Pathology, School of Medical Sciences, Clinical Teaching Center, University of Cape Coast, Private Mail Bag, Cape Coast, Ghana.
Cervical cancer continues to disproportionately burden women in sub-Saharan Africa, and is the commonest gynecological cancer in Ghana. The Cervical Cancer Prevention and Training Centre (CCPTC), Battor, Ghana spearheaded the Ghana arm of the mPharma 10,000 Women Initiative (mTTWI) between September 2021 and October 2022. The aim of this study was to examine the outcomes of nationwide concurrent screening using high-risk human papillomavirus (hr-HPV) DNA testing and visual inspection methods, as well as factors associated with the screening outcomes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!